Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agenus Inc. filings document the regulatory record for a clinical-stage immuno-oncology company developing antibody-based cancer therapies, led by the BOT+BAL program of botensilimab and balstilimab. Its Form 8-K reports cover periodic financial results, clinical-program and access-program updates, material agreements, securities-related amendments and the completed disposition of manufacturing assets with related license arrangements.
Proxy and governance filings describe board matters, executive compensation, shareholder voting items and equity awards. Other event reports document officer appointments, capital-structure changes, unregistered securities activity and legal or regulatory matters affecting the company's public-company disclosures.
Agenus (Nasdaq: AGEN) filed an 8-K detailing the results of its 17 June 2025 Annual Meeting, where 16.71 million shares—61.5 % of shares outstanding—were represented.
Board elections: Class I directors Brian Corvese (5.99 m for / 4.83 m withheld) and Timothy Wright (6.86 m for / 3.96 m withheld) were elected to serve until 2028.
Equity & compensation matters:
- Stockholders approved expanding the 2019 Equity Incentive Plan to 12.05 m shares, adding 7.0 m shares (6.14 m for / 4.59 m against / 0.08 m abstain).
- They approved raising share limits on the Directors’ Deferred Compensation Plan (+25 k shares) and the 2019 ESPP (+50 k shares).
- A one-time option exchange was rejected (4.87 m for / 5.82 m against).
- The advisory say-on-pay resolution was also rejected (5.16 m for / 5.18 m against).
Audit: KPMG LLP was ratified for FY 2025 (13.62 m for / 2.87 m against).
The voting pattern shows notable shareholder resistance to current compensation practices—even as additional share reserves for future equity awards were endorsed—signalling potential governance scrutiny ahead.
Agenus (NASDAQ: AGEN) filed a Form 4 disclosing that director Timothy Wright received a total of 15,750 stock options on 06/17/2025 under the company’s 2019 Amended & Restated Equity Incentive Plan.
The options carry an exercise price of $3.02 and expire on 05/28/2035. Two tranches were awarded: 750 options that vest one-third on 05/28/2026 and quarterly thereafter, and 15,000 options that vest fully one year after the grant date. All awards were reported as directly held; no shares were sold or otherwise disposed. The filing is a routine disclosure of director compensation rather than a change in ownership of common stock.
Form 4 Filing Overview – Agenus Inc. (AGEN)
Director Susan B. Hirsch reported the receipt of 15,000 non-qualified stock options under the company’s 2019 Amended & Restated Equity Incentive Plan. The grant was originally approved on 28 May 2025, became effective upon shareholder approval at the 17 June 2025 annual meeting, and is therefore shown as the transaction date. Key terms are:
- Exercise price: $3.02 per share
- Vesting: 100 % on the one-year anniversary of the grant date (28 May 2026)
- Expiration: 28 May 2035 (10-year term)
- Post-transaction holdings: 15,000 derivative securities (stock options) held directly
No purchases or sales of Agenus common stock were reported, and no non-derivative holdings changed. The filing therefore represents a routine equity award intended to align director incentives rather than an open-market transaction that would signal confidence or concern about near-term fundamentals. At approximately 15 k shares, potential dilution is de-minimis relative to Agenus’ outstanding share count.
Agenus (NASDAQ: AGEN) filed a Form 4 disclosing that director Brian Corvese received two option grants totaling 30,750 derivative securities on 06/17/2025, following shareholder approval of the 05/28/2025 grant date.
The options carry a $3.02 exercise price and expire on 05/28/2035. A 750-unit grant vests one-third on 05/28/2026 with quarterly vesting thereafter, while the larger 30,000-unit grant vests fully on the one-year anniversary of the grant date. No common shares were bought or sold, so Corvese’s direct ownership only increased by the new option awards.
Agenus (NASDAQ: AGEN) filed a routine Form 4 disclosing an equity award to Christine M. Klaskin, the company’s Principal Financial and Accounting Officer. On 06/17/2025, Klaskin was granted 7,250 stock options with a strike price of $3.02 per share under the 2019 Amended & Restated Equity Incentive Plan. The award had been approved by shareholders the same day. One-third of the options vest on 05/28/2026, with the balance vesting in equal quarterly installments thereafter, and the options expire on 05/28/2035. No shares were sold or otherwise disposed of, and Klaskin’s beneficial ownership increased by the option amount. The transaction appears to be a standard, non-material compensation grant rather than a market-moving insider trade.